Single Dose Inamrinone in Terminal Warm Cardioplegia in On-Pump Coronary Artery Bypass Patients 9
When given directly into the heart with terminal warm
cardioplegia the expected improvements in hemodynamics
are prominent but the strong vasodilatation seen with
intravenous use is decreased.
The study was funded by Elma Larsson Foundation
and Los Angeles Thoracic and Cardiovascular Foundation.
Los Angeles, USA.
REFERENCES
[1] M. Kikura and S. Sato, “The Efficacy of Preemptive Mil-
rinone or Amrinone Therapy in Patients Undergoing
Coronary Artery Bypass Grafting,” Anesthesia & Analgesia,
Vol. 94, No. 1, 2002, pp. 22-30.
[2] J.-F. Hardy, N. Searic, M. Roy and J. Perrault, “Amrinone,
in Combination with Norepinephrine, Is an Effective
First-Line Drug for Difficult Separation from Cardiopul-
monary Bypass,” Canadian Journal of Anesthesia, Vol.
40, No. 6, 1993, pp. 495-501.
[3] T. Yamada, J. Takeda, N. Katori, K. Tsuzaki and R.
Ochial, “Hemodynamic Effect s of Milrinone during We an-
ing from Cardiopulmonary Bypass: Comparison of Pa-
tients with a Low and High Prebypass Cardiac Index,”
Journal of Cardiothoracic and Vascular Anesthesia, Vol.
14, No. 4, 2000, pp. 367-373. doi:10.1053/jcan.2000.7920
[4] Y. Hamada, K. Kawachi, T. Yamamoto, T. Nakata, Y.
Kashu, M. Sato and Y. Watanabe, “Effects of single ad-
ministration of a phophodiesterase III inhibitor during
cardiopulmonary bypass. Comparison of Milrinone and
Amrinone,” Japanese Circulation Journal, Vol. 63, No. 8,
1999, pp. 605-6095. doi:10.1253/jcj.63.605
[5] Y. Ko, K. Morita, R. Nagahori, K. Kinouchi, G. Shino-
hara, H. Kagawa and H. Hashimoto, “Myocardial Cyclic
AMP Augmentation with High-Dose PDE III Inhibitor in
Terminal Warm Blood Cardioplegia,” Annals of Thoracic
and Cardiovascular Surgery, Vol. 15, No. 5, 2009, pp.
311-316.
[6] K. J. Fogg and D. Royston, “Improved Performance with
Single Dose Phosphodiesterase Inhibitor (Editorial),” Bri-
tish Journal of Anaesthesia, Vol. 81, No. 5, 1998, pp.
663-666.
[7] M. Kikura, J. H. Levy, J. M. Bailey, J. S. Sha ne wise, L. G.
Michelsen and S. M. Sadel, “A Bolus Dose of 1.5 mg/kg
Amrinone Effectively Improves Low Cardiac Output S tate
Following Separation from Cardiopulmonary Bypass in
Cardiac Surgical Patients,” Acta Anaesthesiologica Scan-
dinavica, Vol. 42, No. 7, 1998, pp. 825-833.
doi:10.1111/j.1399-6576.1998.tb05329.x
[8] J. P. Rathmell, R. C. Prielipp, J. F. Butterworth, E. Wil-
liams, F. Villamaria, L. Testa, C. Viscomi, F. P. Ittleman,
E. C. Baisden and L. R. Royster, “A Multicenter, Ran-
domized, Blind Comparison of Amrinone with Milrinone
after Elective Cardiac Surgery,” Anesthesia & Analgesia,
Vol. 86, 1998, pp. 683-690.
[9] P. L. Ludmer, R. F. Wright, J. M. Arnold, P. Ganz, E.
Braunwald and W. S. Colucci, “Separation of the Direct
Myocardial and Vasodilator Actions of Milrinone Ad-
ministered by Intracoronary Infusion Technique,” Circu-
lation, Vol. 73, No. 1, 1986, pp. 130-137.
doi:10.1161/01.CIR.73.1.130
[10] R. J. Benotti, W. Grossman, E. Braunwald, D. D. Davolos
and A. A. Alousi, “Hemodynamic Assessment of Amri-
none,” New England Journal of Medicine, Vol. 299, 1978,
pp. 1373-1377. doi:10.1056/NEJM197812212992501
[11] K. P. Lewis, I. R. Appadurai, E. T. Pierce, E. F. Halpern
and R. H. Bode Jr., “Prophylactic Amrinone for Weaning
from Cardiopulmonary Bypass,” Anaesthesia, Vol. 55,
No. 7, 2000, pp. 627-633.
doi:10.1046/j.1365-2044.2000.01372.x
[12] J. F. Butterworth, R. L. Royster, R. C. Prielipp, S. T.
Lawless and S. L. Wallenhaupt, “Amrinone in Cardiac
Surgical Patients with Left Ventricular Dysfunction. A
Prospective, Randomized Placeo-Controlled Trial,” Chest,
Vol. 104, No. 6, 1993, pp. 1660-1667.
doi:10.1378/chest.104.6.1660
[13] M. Gillies, R. Bellomo, L. Doolan and B. Buxton, “B e nc h -
to-Bedside Review: Inotropic Drug Therapy after Adult
Cardiac Surgery—Systematic Literature Review,” Criti-
cal Care, Vol. 9, No. 3, 2005, pp. 266-279.
[14] M. Arbeus, B. Axelsson, O. Friberg, A. Magnuson, L.
Bodin and J. Hultman, “Milrinone Increases Flow in
Coronary Artery Bypass Grafts after Cardiopulmonary
Bypass: A Prospective, Randomized, Double-Blind, Pla-
cebo-Controlled Study,” Journal of Cardiothoracic and
Vascular Anesthesia, Vol. 23, No. 1, 2009, pp. 48-53.
doi:10.1053/j.jvca.2008.07.005
[15] E. B. Lobato, F. Urdaneta, T. D. Martin and N. Graven-
stein, “Effects of Milrinone versus Epinephrine on Grafted
Internal Mammary Artery Flow after Cardiopulmonary
Bypass,” Journal of Cardiothoracic and Vascular Anes-
thesia, Vol. 14, No. 1, 2000, pp. 9-11.
doi:10.1016/S1053-0770(00)90047-8
[16] V. Simkova, P. Radermacher and E. Barth, “Metabolic
Effects of Phosphodiesterase III Inhibitors: Another Rea-
son to Promote Their Use?” Critical Care, Vol. 11, 2007,
pp. 139-140. doi:10.1186/cc5924
[17] M. Jebeli, M. Ghazinoor, M. H. Mandegar, M. R. Rasouli,
P. Eghtesadi-Araghi, H. Goodarzynejad , R. Mohaamadzadeh,
A. Darehzereshki and S. Dianat, “Effect of Milrinone on
Short-Term Outcome of Patients with Myocardial Dys-
function Undergoing Coronary Artery Bypass Graft: A
Randomized Controlled Trial,” Cardiology Journal, Vol.
17, No. 1, 2010, pp. 73-78.
[18] M. Heringlake, M. Wernerus, J. Grünfeld, S. Klaus, H.
Heinze, M. Bechtel, L. Bahlmann, J. Poeling and J. Schön,
“The Metabolic and Renal Effects of Adrenaline and Mil-
rinone in Patients with Myocardial Dysfunction after
Coronary Artery Bypass,” Critical Care, Vol. 11, No. 2,
2007, pp. R51-R61. doi:10.1186/cc5904
[19] G. A. Fleming, K. T. Murray, C. Yu, J. G. Byrne, J. P.
Greelish, M. R. Petracek, S. J. Hoff, S. K. Ball, N. J.
Brown and M. Pretorius, “Milrinone Use Is Associated
with Postoperative Atrial Fibrillation after Cardiac Sur-
gery,” Circulation, Vol. 118, No. 16, 2008, pp. 1619-
1625. doi:10.1161/CIRCULATIONAHA.108.790162
Copyright © 2012 SciRes. OJTS